BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts
2015/07/01 by I Lohse, Ines Lohse, Ayelet Borgida +21 · 26 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Pancreatic and Hepatic Oncology Research #PARP inhibition in cancer therapy #Cancer Genomics and Diagnostics
paper · pdf · doi:10.1038/bjc.2015.220
Abstract
BACKGROUND: Germline mutations of the BRCA tumour suppressors have been associated with increased risk of pancreatic cancer. Clinical evidence suggests that these patients may be more sensitive to treatment with cisplatin. As the frequency of germline BRCA mutations is low, definitive experimental data to support the clinical observations are still missing. METHODS: We tested gemcitabine and cisplatin sensitivity of four BRCA1 and BRCA2 mutant and three BRCA1 and BRCA2 wild-type (WT) patient-derived pancreatic cancer xenografts. RESULTS: We observed treatment sensitivity to gemcitabine and cisplatin in the BRCA WT and mutant models. The BRCA1 and BRCA2 mutant xenografts were significantly more sensitive to cisplatin although these models also showed sensitivity to gemcitabine. The BRCA1 and BRCA2 WT models showed sensitivity to gemcitabine but not cisplatin. Treatment sensitivity in the xenograft models closely resembled treatment response in the corresponding patients. DISCUSSION: We have characterised a panel of xenografts derived from pancreatic cancer patients carrying germline BRCA mutations, and shown that their genetic features resemble the patient donor. Our results support further clinical testing of treatment regimens combining gemcitabine and platinum drugs in this patient population, as well as preclinical research aiming to identify mechanisms of cisplatin resistance in BRCA mutant pancreatic cancers.
Cited by
- Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer
- Cytokinetic effects of Wee1 disruption in pancreatic cancer. [europepmc]
- Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer? [europepmc]
- KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer. [europepmc]
- Current status and perspectives of patient-derived xenograft models in cancer research. [europepmc]
- Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer. [europepmc]
- BRCA1 expression serves a role in vincristine resistance in colon cancer cells. [europepmc]
- Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. [europepmc]
- Prostate cancer in the era of "Omic" medicine: recognizing the importance of DNA damage repair pathways. [europepmc]
- Inhibiting the MCM8-9 complex selectively sensitizes cancer cells to cisplatin and olaparib. [europepmc]
- Familial Pancreatic Cancer and Surveillance of High-Risk Individuals. [europepmc]
- IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2. [europepmc]
- PRIMPOL-Mediated Adaptive Response Suppresses Replication Fork Reversal in BRCA-Deficient Cells. [europepmc]
- Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains. [europepmc]
- Pathogenesis and Treatment of Pancreatic Cancer Related Pain. [europepmc]
- BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects. [europepmc]
- Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer. [europepmc]
- Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma. [europepmc]
- Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer. [europepmc]
- Fangchinoline suppresses conjunctival melanoma by directly binding FUBP2 and inhibiting the homologous recombination pathway. [europepmc]
- DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives. [europepmc]
- Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy. [europepmc]
- CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy. [europepmc]
- Crosstalk between Ca 2+ Signaling and Cancer Stemness: The Link to Cisplatin Resistance. [europepmc]
- Downregulation of TAB182 promotes cancer stem-like cell properties and therapeutic resistance in triple-negative breast cancer cells. [europepmc]
- Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency. [europepmc]
Related